Celgene Corporation (NASDAQ: CELG) is a manufacturer of drug therapies for cancer and inflammatory disorders. It is incorporated in Delaware and headquartered in Summit, New Jersey. The company's major products are THALOMID (thalidomide), which is approved for the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum ("ENL"), as well as in combination with dexamethasone for patients with newly diagnosed multiple myeloma, and REVLIMID (lenalidomide), for which the company has received FDA and EMEA approval in combination with dexamethasone for the treatment of multiple myeloma patients who have received at least one prior therapy. REVLIMID is also approved in the United States for the treatment of patients with transfusion-dependent anemia due to Low- or Intermediate-1-risk MDS associated with a deletion 5q cytogenetic abnormality with or without additional cytogenetic abnormalities. Both THALOMID and REVLIMID are sold through proprietary risk-management distribution programs to ensure safe and appropriate use of these pharmaceuticals. Celgene also receives royalties from Novartis Pharma AG on sales of the entire RITALIN family of drugs, which are widely used to treat Attention Deficit Hyperactivity Disorder (ADHD).
Some of this data may be out of date
State influence data from the National Institute on Money in State Politics changed in format and availability during the 2013-2014 election cycle. While we work to integrate their new style of data release, state-level campaign finance data for the 2014 cycle and beyond will be unavailable. We apologize for the inconvenience, but heartily recommend trying out their snazzy new site at FollowTheMoney.org!
Campaign Finance$1,068,515 Given
Figures are based on itemized contributions reported to the Federal Election Commission and state agencies. Please note that:
- contributions under $200 are not reported, and so are not included in totals.
- only contributions from individuals and organizations to candidates are included. Various accounting measures and more exotic contribution types are excluded.
- contributions are matched based on organization and recipient name reported within each election cycle. Contributions using an incorrect or non-standard version of the name may be missed.
- corporate name changes and mergers may cause figures to differ from those of the Center for Responsive Politics.
- organization totals include known subsidiaries of the organization.
state-level data is not available in bulk for 2014. for current state data, browse http://followthemoney.org/
- PAC Color Block
- Organization's PAC(s)
- Employee Color Block
- Associated Individuals
Republicans vs. Democratsin dollars. "Other" includes 3rd parties and organizations without official party affiliation.
State vs. Federalin dollars
Top PAC Recipients
- PAC Color Block
- Organization's PAC(s)
- Employee Color Block
- Associated Individuals
Figures are based on lobbying activity reported to the Senate Office of Public Records. Reported dollar amounts are required to be accurate only to the nearest $20,000. For organizations whose primary business is lobbying, we display total income and top clients. For organizations that are not primarily lobbying firms, we display total amount spent on lobbying and top lobbying firms hired.
For more information, please see our lobbying methodology page.
Lobbying on Behalf of Celgene Corp
Names of Lobbyists
Firm Hired Amount Celgene Corp $8,174,000
Most Frequently Disclosed Lobbying Issues
- Health Issues,
- Medicare & Medicaid,
- Copyright, Patent & Trademark,
- Fed Budget & Appropriations,
- Medical Research & Clin Labs,
- Veterans Affairs,
- Science & Technology
Most Frequently Disclosed Bills
Bill No. Title H.R.2672 Preserving Access to Orphan Drugs Act of 2011 S.1423 Preserving Access to Orphan Drugs Act of 2011 H.R.1249 America Invents Act S.23 Patent Reform Act of 2011 H.R.444 340B Program Improvement and Integrity Act of 2009 H.R.4213 Tax Extenders Act of 2009 S.1239 340B Program Improvement and Integrity Act of 2009
RegulationsMentioned in 82 dockets; Submitted to 17 dockets
All data is based on documents downloaded from Regulations.gov. The first table shows mentions: all documents that include the name of the company anywhere in the document or document metadata. The second table shows submissions: all documents where the submitter metadata included the company name. Each table shows the top 10 dockets, ranked by number of occurrences.
Matches are based on a search for the company name. Variations in the company name, such as acronyms, nicknames or alternate names may cause documents to be missed. The mention of a company name in a document may be incidental and does not necessarily indicate that the company has any relevance to the document. Company names that are common English words may erroneously match with text that is not referring to the company.
Not all agencies submit public comments to Regulations.gov. For a list of participating and non-participating agencies see here. Agencies that do submit to Regulations.gov have varying levels of accuracy and completeness.
Regulations and public comments can be downloaded in bulk here.
The tables show occurrences of "Celgene Corp" in public comments on proposed federal regulations.
Documents Submitted by the Organization
View all submissions data for Celgene Corp
- Toggle 2 FDA Risk Evaluation and Mitigation Strategies for Certain Opioid Drugs; Notice of Public Meeting 2009
- Toggle 1 FDA Guidance for Industry on Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling 2006
- Toggle 1 FDA Good Laboratory Practice for Nonclinical Laboratory Studies 2010
- Toggle 1 FDA Best Practices for Communication Between FDA and IND Sponsors During Drug Development; Request for Comments 2014
- Toggle 1 FDA Standardizing and Evaluating Risk Evaluation and Mitigation Strategies; Notice of Public Meeting; Request for Comments 2013
- Toggle 1 FDA Draft Guidance for Industry on Bioanalytical Method Validation 2013
- Toggle 1 HHS Guidance on Exculpatory Language in Informed Consent, Draft 2011
- Toggle 1 FDA Refrain from approving Any Application for a Generic Thalidomide Product 2007
- Toggle 1 FDA FDA Transparency Task Force; Public Meeting 2009
- Toggle 1 FDA Draft Guidance for Industry on Principles for Considering Whether an FDA-Regulated Product Involves the Application of Nanotechnology; Availability 2010
Mentions in Document Text
View all mentions data for Celgene Corp
- Toggle 50 FDA Petition to Require Celgene Corporation to Revise the Labeling of Thalomid Capsules to Strengthen Warnings of the Potential for Serious Adverse Events When Prescribed in Combination with other Cancer Treatment Therapies 2005
- Toggle 24 FDA Refrain from approving Any Application for a Generic Thalidomide Product 2007
- Toggle 7 FDA Patent Extension Application for REVLIMID (lenalidomide), U.S. Patent No. 5,635,517 2006
- Toggle 4 FDA Requesting that the FDA establish stringent standards with respect to any abbreviated new drug application relying on the approval of ABRAXANE as a reference listed drug, and any 505 b 2 new drug application for any similar product referencing ABRAXANE or paclitaxel. 2015
- Toggle 3 FDA Guidance for Industry on Drug Interaction Studies-Study Design, Data Analysis, and Implications for Dosing and Labeling 2006
- Toggle 3 FDA Enforce the FDC Act to Prevent the Use of REMS to Block or Delay Generic Competition 2009
- Toggle 2 FDA Orphan Product Designations 1984
- Toggle 2 FDA Implementation of Risk Minimization Action Plans (RiskMAPs) to Support Quality Use of Pharmaceuticals: Opportunities and Challenges; Public Workshop 2007
- Toggle 2 FDA Patent Extension Application for POMALYST® Patent No. 8,198,262 2014
- Toggle 2 FDA Standardizing and Evaluating Risk Evaluation and Mitigation Strategies; Notice of Public Meeting; Request for Comments 2013
Federal Spending4 grants
Federal grants, contracts and loans are reported by federal agencies using the FPDS and FAADS systems. The data is made available to the public at USASpending.gov. Please note that the completeness and quality of the data varies greatly by agency.
Only grants, contracts and loans with amounts over $1 million are shown.
Because company names are not reported in a standardized manner, we cannot reliably determine the company receiving the contract or award. The results shown here are based on a search for the company name. Individual records may be missed or erroneously included because of name variations. For more information, please see our federal spending methodology page.
Note: Company names in federal spending data are not standardized. The table below is included only as a sample of what is available in the data and has not been reviewed for accuracy or completeness. To investigate the data further, use the links at the bottom of the table.
|Celgene Corporation||2012||Defense Advanced Research Projects Agency (Darpa)||LARGE-SCALE PRODUCTION OF HSC-DERIVED,GENE-MODIFIED RED BLOOD CELLS||$7,489,743|
|Celgene Corporation||2011||Dept Of The Air Force||TAS::57 3600::TAS"Large-Scale Human Placenta Progenitor Cell-Derived Erythrocyte Production - Continuous Red Blood Cell Production"||$3,687,247|
|Celgene Corporation||2009||Dept Of Defense||"Large-Scale Human Placenta Progenitor Cell-Derived Erythrocyte Production - Continuous Red Blood Cell Production" 28 Sep 07||$3,170,533|
|Celgene Corporation||2011||Dept Of The Air Force||TAS::57 3600::TAS "Large-Scale Human Placenta Progenitor Cell-Derived Erythrocyte Production - Continuous Red Blood Cell Production"||$1,400,000|